Skip to content
Sign in
StableHealthReported 2026-11-09 16:32

Shareholder fraud investigation launched after Tenax Therapeutics Phase 3 trial failure

Schall, Brown & Schwartz LLP announced an investigation into Tenax Therapeutics (NASDAQ: TENX) for alleged securities law violations following the company's disclosure that its Phase 3 LEVEL trial of TNX-103 failed to meet primary and secondary endpoints, causing shares to drop nearly 90%.

Why it matters. Investors who suffered losses may have grounds to join a securities class action; the trial failure represents a material setback for the company's lead drug candidate and its development pipeline.

01

Who and what it touches

Cardiopulmonary thera…produceslevosimendanusespharmaceutical indust…operates inSan Diegolocated inSecurities Exchange A…regulated byTNX-103suppliesTenax Therapeut…

From Tenax Therapeutics, Inc.

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-09 16:32
    Tenax revealed that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints.
    View source
  • PPR Newswire news releasesCompany2026-11-07 08:38
    Tenax revealed that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints.
    View source